European Journal of Endocrinology · 2012 · 128 citations · 21 references
MedicineOncologyCancer Drug Toxicity ManagementOncology PharmacotherapyTumor ProgressionResponse AssessmentThyroid CancerToxicity ManagementHand-foot Syndrome ManagementLong-term EffectivenessPartial Response AssessmentPhase Ii Clinical TrialsRadioactive Iodine FailureRefractory Solid TumorsRefractory Thyroid CarcinomaSorafenib Therapy
OBJECTIVE: We conducted a prospective phase II clinical trial to determine the efficacy of sorafenib in patients with advanced radio-iodine refractory differentiated thyroid cancer. In this article, the long-term results are presented. PATIENTS AND METHODS: Thirty-one patients with progressive metastatic or locally advanced radioactive iodine refractory differentiated thyroid cancer received sorafenib 400 mg orally twice daily. The study end points included response rate, progression-free survival (PFS), overall survival (OS), best response by Response Evaluation Criteria in Solid Tumors criteria 1.0, and toxicity. RESULTS: Median PFS was 18 months (95% confidence interval (95% CI): 7-29 months) and median OS was 34.5 months (95% CI: 19-50 months). Eight patients (31%) achieved a partial response and 11 patients (42%) showed stable disease after a median follow-up of 25 months (range 3.5-39 months). Toxicity mostly included hand foot syndrome, weight loss, diarrhea, and rash. CONCLUSION: Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer. Sorafenib can nowadays be considered as the standard option in these patients.
21
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Vandana G. Abramson, Andrea B. Troxel, Anoma Nellore et al. · Journal of Clinical Oncology · 2008 · 679 citations · Full text
Medicine, Oncology, Pharmacology +6
Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi et al. · International Journal of Cancer · 2007 · 547 citations
Medicine, Oncology, Pharmacology +17